Drugs / Sandostatine®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02012166 Background | Jul → Dec 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sandostatine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02012166 ↗ |
| Route | Intravenous | “Intravenous Sandostatine® will be administered at 30 ng/kg/min.” NCT02012166 ↗ |